Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loxonin Tape is a transdermal patch formulation of loxoprofen sodium hydrate, a prodrug-type nonsteroidal anti-inflammatory drug (NSAID) in the propionic acid derivative group. Developed and manufactured by Lead Chemical Co., Ltd., it works by inhibiting cyclooxygenase (COX) enzymes, which reduces the synthesis of prostaglandins responsible for inflammation and pain. The patch is applied once daily to the affected area, allowing the drug to be absorbed through the skin and converted into its active trans-OH metabolite. This localized delivery system is approved for treating osteoarthritis, muscle pain (myalgia), and post-traumatic swelling and pain, offering a therapeutic alternative that may reduce the systemic side effects associated with oral NSAID administration, such as gastrointestinal, cardiovascular, and renal complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Loxonin Tape.